Q-and-A: FDA's Robert Temple discusses off-label promotion

12/3/2007 | RPM Report (free registration), The

Robert Temple, who heads up the medical policy office at the FDA's Center for Drug Evaluation & Research, emphasizes that off-label promotion rules for drug companies are clear in their prohibition of the practice, but that some off-label use, as prescribed by doctors, can provide reasonable and appropriate treatments and can offer treatment options when no others are available for certain conditions.

View Full Article in:

RPM Report (free registration), The

Published in Brief:

SmartBrief Job Listings for Health Care